ranolazine has been researched along with Non-alcoholic Fatty Liver Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eaton, F; Gopal, K; Greenwell, AA; Saed, CT; Tabatabaei Dakhili, SA; Ussher, JR | 1 |
| Al Batran, R; Chan, JSF; Eaton, F; Gopal, K; Greenwell, AA; Saed, CT; Tabatabaei Dakhili, SA; Ussher, JR; Yang, K | 1 |
| Athyros, VG; Doumas, M; Imprialos, KP; Stavropoulos, K | 1 |
3 other study(ies) available for ranolazine and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
The anti-anginal ranolazine does not confer beneficial actions against hepatic steatosis in male mice subjected to high-fat diet and streptozotocin-induced type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Ranolazine; Streptozocin; Triglycerides | 2022 |
The antianginal ranolazine fails to improve glycaemia in obese liver-specific pyruvate dehydrogenase deficient male mice.
Topics: Animals; Diet, High-Fat; Glucose; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Oxidoreductases; Ranolazine | 2023 |
The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease.
Topics: Coronary Artery Disease; Humans; Liver Function Tests; Non-alcoholic Fatty Liver Disease; Ranolazine | 2022 |